TWI926045B - 含氮雜環類化合物、其製備方法及其在醫藥上的應用 - Google Patents

含氮雜環類化合物、其製備方法及其在醫藥上的應用

Info

Publication number
TWI926045B
TWI926045B TW111119308A TW111119308A TWI926045B TW I926045 B TWI926045 B TW I926045B TW 111119308 A TW111119308 A TW 111119308A TW 111119308 A TW111119308 A TW 111119308A TW I926045 B TWI926045 B TW I926045B
Authority
TW
Taiwan
Prior art keywords
compound
halogen
general formula
alkyl
cancer
Prior art date
Application number
TW111119308A
Other languages
English (en)
Chinese (zh)
Other versions
TW202313630A (zh
Inventor
李心
董懷德
蔡國棟
賀峰
陶維康
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202313630A publication Critical patent/TW202313630A/zh
Application granted granted Critical
Publication of TWI926045B publication Critical patent/TWI926045B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW111119308A 2021-05-24 2022-05-24 含氮雜環類化合物、其製備方法及其在醫藥上的應用 TWI926045B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202110565410 2021-05-24
CN202110565410.0 2021-05-24
CN202110694022 2021-06-22
CN202110694022.2 2021-06-22
CN202110856289.7 2021-07-28
CN202110856289 2021-07-28
CN202210198679.4 2022-03-02
CN202210198679 2022-03-02

Publications (2)

Publication Number Publication Date
TW202313630A TW202313630A (zh) 2023-04-01
TWI926045B true TWI926045B (zh) 2026-05-21

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111119308A TWI926045B (zh) 2021-05-24 2022-05-24 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Country Status (11)

Country Link
US (1) US20240287094A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349836A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519188A (cg-RX-API-DMAC7.html)
KR (1) KR20240012437A (cg-RX-API-DMAC7.html)
CN (1) CN117177971A (cg-RX-API-DMAC7.html)
AU (1) AU2022280845A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022496A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219858A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013890A (cg-RX-API-DMAC7.html)
TW (1) TWI926045B (cg-RX-API-DMAC7.html)
WO (1) WO2022247816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
KR20250103773A (ko) * 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
JP2026524090A (ja) 2023-06-08 2026-07-17 上海森▲輝▼医▲葯▼有限公司 ホルムアミド系化合物の製造方法
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
WO2020098774A1 (zh) * 2018-11-16 2020-05-22 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
WO2021013735A1 (en) * 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途

Also Published As

Publication number Publication date
BR112023022496A2 (pt) 2024-01-16
CA3219858A1 (en) 2022-12-01
KR20240012437A (ko) 2024-01-29
CN117177971A (zh) 2023-12-05
EP4349836A4 (en) 2024-10-30
EP4349836A1 (en) 2024-04-10
US20240287094A1 (en) 2024-08-29
WO2022247816A1 (zh) 2022-12-01
AU2022280845A1 (en) 2023-12-14
TW202313630A (zh) 2023-04-01
MX2023013890A (es) 2023-12-11
JP2024519188A (ja) 2024-05-08

Similar Documents

Publication Publication Date Title
EP4273136A4 (en) NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, METHOD OF PREPARING THE SAME AND MEDICAL USE THEREOF
EP4209490A4 (en) CONDENSED IMIDAZOLE DERIVATIVE, PROCESS THEREOF AND MEDICAL USE THEREOF
EP3907218A4 (en) 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE
EP4015520A4 (en) OXYGEN-CONTAINING HETEROCYCLIC COMPOUND, PROCESS FOR THEIR PRODUCTION AND ITS USE
EP3865488A4 (en) MACROCYCLIC COMPOUND AS CDK INHIBITOR, METHOD OF MANUFACTURING AND MEDICAL USE
EP3539963A4 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE
EP4023659A4 (en) COMPOUND AND DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF
EP4308549A4 (en) Nitrogen-containing heterocyclic ketones, manufacturing processes and medicinal uses thereof
EP4349828A4 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PRODUCTION PROCESS THEREOF AND USE THEREOF
EP3919489A4 (en) AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE
EP4289843A4 (en) PYRIDOPYRIMIDINONE DERIVATIVE, MANUFACTURE PROCESS THEREOF AND USE THEREOF
EP3992194A4 (en) BENZODIAZEPIN COMPOUND, METHOD OF MANUFACTURE AND USE THEREOF IN MEDICINE
EP4238958A4 (en) 2-CYANOACRYLATE COMPOUND, METHOD FOR PREPARING IT AND ITS USE
EP4159733A4 (en) BETA-LACTAM COMPOUND, USE THEREOF AND METHOD OF MANUFACTURING THEREOF
EP4108766A4 (en) Method for preparing fibrosis-encapsulated tumoroid, and use thereof
EP4585596A4 (en) Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
ZA202209741B (en) Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof
EP4065553A4 (en) NEW COMPOUND, METHOD FOR PREPARATION AND USE
EP4082556A4 (en) PREPARATION OF COMPOUND FOR NERVOUS TISSUE REGENERATION, METHOD FOR PREPARATION AND USE
HK40112858A (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
HK40104924A (en) Nitrogen-containing heterocyclic compound, and preparation method thereof, intermediate thereof, and application thereof
CA3274002A1 (en) Heterocyclic compound, and preparation method therefor and use thereof
HK40121001A (en) Heterocyclic compound, and preparation method therefor and use thereof
HK40122720A (en) Heterocyclic compound, method for preparing same, and pharmaceutical use thereof
CA3264205A1 (en) Heterocyclic compound, method for preparing same, and pharmaceutical use thereof